Baricitinib for COVID-19: a suitable treatment?
作者信息
Favalli Ennio G, Biggioggero Martina, Maioli Gabriella, Caporali Roberto
机构信息
Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan 20122, Italy.
Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan 20122, Italy.
出版信息
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
Abstract
摘要
相似文献
1
Baricitinib for COVID-19: a suitable treatment?
Lancet Infect Dis. 2020 Sep;20(9):1012-1013. doi: 10.1016/S1473-3099(20)30262-0. Epub 2020 Apr 3.
2
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Lancet Infect Dis. 2020 Sep;20(9):1013-1014. doi: 10.1016/S1473-3099(20)30270-X. Epub 2020 Apr 3.
3
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.
4
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
Expert Opin Drug Saf. 2020 Oct;19(10):1367-1369. doi: 10.1080/14740338.2020.1812191. Epub 2020 Aug 25.
5
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
6
Can artificial intelligence identify effective COVID-19 therapies?
EMBO Mol Med. 2020 Aug 7;12(8):e12817. doi: 10.15252/emmm.202012817. Epub 2020 Jul 7.
7
[Baricitinib in the treatment of SARS-CoV-2 infection].
Rev Esp Quimioter. 2020 Aug;33(4):294-295. doi: 10.37201/req/047.2020. Epub 2020 Jun 25.
8
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
9
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11.
10
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.
引用本文的文献
1
Comprehensive and translational pathobiology of COVID-19 based on cellular and molecular techniques.
Pract Lab Med. 2025 Aug 11;46:e00497. doi: 10.1016/j.plabm.2025.e00497. eCollection 2025 Sep.
2
Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease.
Mol Divers. 2025 Jul 3. doi: 10.1007/s11030-025-11247-x.
3
[Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology].
Rev Colomb Reumatol. 2020 Jul-Sep;27(3):230-241. doi: 10.1016/j.rcreu.2020.05.007. Epub 2020 Jun 12.
4
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].
Med Intensiva. 2021 Mar;45(2):104-121. doi: 10.1016/j.medin.2020.06.017. Epub 2020 Jul 11.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
6
Coronavirus Disease 2019 in Rheumatic Patients with Inflammatory Disorders: A Descriptive Study from a High Infection Incidence Region of Northern Spain.
Eur J Rheumatol. 2023 Oct;10(4):136-142. doi: 10.5152/eurjrheum.2023.21152.
7
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
8
Development of Diphenyl carbonate-Crosslinked Cyclodextrin Based Nanosponges for Oral Delivery of Baricitinib: Formulation, Characterization and Pharmacokinetic Studies.
Int J Nanomedicine. 2023 Apr 27;18:2239-2251. doi: 10.2147/IJN.S405534. eCollection 2023.
9
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.
J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15.
10
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.
Front Immunol. 2023 Mar 22;14:1147991. doi: 10.3389/fimmu.2023.1147991. eCollection 2023.
本文引用的文献
1
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
2
Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019.
3
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.
4
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists.
Vaccines (Basel). 2016 Jun 29;4(3):23. doi: 10.3390/vaccines4030023.
5
How to approach and treat viral infections in ICU patients.
BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/1471-2334-14-321.
Zotero 插件